Learn About Peptides

Everything you need to know about therapeutic peptides, from basic science to clinical applications.

What Are Peptides?

Peptides are short chains of amino acids, the building blocks of proteins. They are essentially small proteins, typically containing between 2 and 50 amino acids linked together by peptide bonds.

Key Definition

Peptide: A molecule consisting of 2-50 amino acids linked by peptide bonds. Larger chains (>50 amino acids) are typically classified as proteins.

Peptides vs. Proteins

Characteristic Peptides Proteins
Size 2-50 amino acids >50 amino acids
Structure Simple, often linear Complex, often folded
Stability Less stable More stable
Absorption Better tissue penetration Limited penetration
Production Chemical synthesis possible Typically requires biological systems

Types of Therapeutic Peptides

🔬 Natural Peptides

Found naturally in the body (e.g., insulin, growth hormone, thymosin). Often replicated synthetically for therapeutic use.

⚗️ Synthetic Peptides

Designed and manufactured in laboratories to mimic or improve upon natural peptides (e.g., BPC-157, TB-500).

💊 Modified Peptides

Natural peptides with chemical modifications to improve stability, absorption, or duration of action (e.g., Semaglutide, Tirzepatide).

🧬 Peptidomimetics

Non-peptide molecules that mimic the biological activity of peptides but with improved drug-like properties.

How Peptides Work

Peptides exert their therapeutic effects by binding to specific receptors on cell surfaces, triggering targeted cellular responses. This receptor-mediated mechanism allows for highly specific actions with minimal off-target effects.

Mechanism of Action

1

Receptor Binding

Peptide binds to specific cell surface receptor with high affinity and selectivity.

→
2

Signal Transduction

Binding triggers intracellular signaling cascades (G-protein, tyrosine kinase, etc.).

→
3

Cellular Response

Signaling leads to specific biological outcomes (gene expression, enzyme activation, etc.).

Common Receptor Types

  • G-Protein Coupled Receptors (GPCRs): Most common target for peptide drugs (e.g., GLP-1 receptor for Semaglutide)
  • Receptor Tyrosine Kinases (RTKs): Involved in growth factor signaling (e.g., insulin receptor)
  • Nuclear Receptors: Regulate gene transcription directly
  • Ion Channel Receptors: Control ion flow across cell membranes

Peptide Synthesis

Therapeutic peptides are manufactured using sophisticated chemical and biological techniques. The choice of method depends on peptide size, complexity, and desired purity.

Solid-Phase Peptide Synthesis (SPPS)

The most common method for producing short to medium-length peptides (2-50 amino acids). Invented by Bruce Merrifield (Nobel Prize, 1984).

SPPS Advantages

  • High purity achievable (>95%)
  • Rapid synthesis (days vs weeks)
  • Automated process
  • Scalable for commercial production

Recombinant DNA Technology

Used for larger, more complex peptides and proteins. Involves inserting peptide-coding genes into bacteria, yeast, or mammalian cells.

Examples: Insulin, growth hormone, erythropoietin

Key Synthesis Steps

  1. Amino acid coupling to solid support
  2. Deprotection of N-terminal
  3. Addition of next amino acid
  4. Repeat until complete sequence
  5. Cleavage from solid support
  6. Purification (HPLC)
  7. Characterization (MS, NMR)

Quality & Purity Testing

Ensuring peptide quality is critical for safety and efficacy. Multiple analytical techniques are used to verify identity, purity, and potency.

Analytical Methods

🔬 HPLC (High-Performance Liquid Chromatography)

Purpose: Measures purity and detects impurities

Standard: >95% purity for pharmaceutical grade

Information provided: Percentage of desired peptide vs degradation products and synthesis byproducts

⚛️ Mass Spectrometry (MS)

Purpose: Confirms molecular identity and weight

Accuracy: ±0.01% molecular weight

Information provided: Exact mass, sequence verification, modification detection

🧪 Amino Acid Analysis (AAA)

Purpose: Verifies amino acid composition

Method: Hydrolysis and chromatographic analysis

Information provided: Confirms correct sequence and quantifies peptide content

🔍 Endotoxin Testing

Purpose: Detects bacterial contamination

Limit: <0.5 EU/mg for injectable peptides

Method: LAL (Limulus Amebocyte Lysate) assay

⚠️ Red Flags for Low Quality

  • No Certificate of Analysis (CoA) provided
  • Purity <90%
  • Unknown or suspicious supplier
  • Unusually low price
  • No batch numbers or testing dates

Routes of Administration

The route of administration profoundly affects peptide bioavailability, pharmacokinetics, onset of action, duration of effect, and patient compliance. Understanding these differences is critical for optimizing therapeutic outcomes.

Key Concept: Bioavailability

Bioavailability is the fraction of an administered dose that reaches systemic circulation in active form. For intravenous (IV) administration, bioavailability is 100% by definition. All other routes have lower bioavailability due to degradation, incomplete absorption, or first-pass metabolism.

Injectable Routes

💉 Subcutaneous (SC) Injection

Most Common for Peptides

Location: Fatty tissue beneath the skin (abdomen, thigh, upper arm, buttocks)

Needle size: 25-31 gauge, 4-8mm length

Bioavailability: 70-90% (varies by peptide and injection site)

Onset of action: 15-30 minutes

Duration: Hours to days (depending on formulation)

Volume limit: 1-2 mL per injection site

Common peptides:

  • Semaglutide (Ozempic/Wegovy)
  • Tirzepatide (Mounjaro/Zepbound)
  • Insulin analogs
  • Growth hormone
  • Tesamorelin
  • BPC-157 (research)
  • TB-500 (research)

Advantages:

  • Easy self-administration after training
  • Steady, sustained absorption
  • Less painful than IM injection
  • Lower risk of nerve/vessel damage
  • Suitable for depot formulations

Disadvantages:

  • Slower absorption than IV/IM
  • Injection site reactions (bruising, redness)
  • Requires proper technique
  • Absorption varies by site and adiposity

Technique tips:

  • Rotate injection sites to prevent lipohypertrophy
  • Pinch skin to create a fold
  • Insert at 45-90° angle
  • Inject slowly and steadily
  • Allow alcohol to dry completely before injection

💪 Intramuscular (IM) Injection

Location: Deep muscle tissue (deltoid, vastus lateralis, gluteus maximus)

Needle size: 21-25 gauge, 1-1.5 inches

Bioavailability: 85-100%

Onset of action: 10-20 minutes

Duration: Hours to weeks (depot formulations)

Volume limit: 2-5 mL (varies by site)

Common peptides:

  • Leuprolide depot (Lupron)
  • Goserelin (Zoladex)
  • Long-acting insulin formulations
  • Some vaccine peptides

Advantages:

  • Faster absorption than SC
  • Higher bioavailability
  • Larger volume capacity
  • Excellent for depot formulations
  • Predictable absorption kinetics

Disadvantages:

  • More painful than SC
  • Difficult for self-administration (some sites)
  • Risk of hitting nerves/blood vessels
  • Muscle damage with repeated injections

🩸 Intravenous (IV) Injection/Infusion

Highest Bioavailability

Location: Directly into vein

Bioavailability: 100% (by definition)

Onset of action: Immediate (seconds to minutes)

Duration: Minutes to hours (depends on half-life)

Common peptides:

  • Insulin (emergency use)
  • Octreotide IV
  • Secretin (diagnostic)
  • Cerebrolysin (in countries where approved)
  • SS-31/Elamipretide (clinical trials)
  • Vasopressin analogs (hospital use)

Advantages:

  • 100% bioavailability guaranteed
  • Rapid onset - critical for emergencies
  • Precise dose control
  • Ability to titrate dose in real-time
  • No first-pass metabolism

Disadvantages:

  • Requires medical professional
  • Risk of infection, phlebitis
  • Expensive and inconvenient
  • Not suitable for home use (usually)
  • Short duration requires infusion pumps

Non-Injectable Routes

💊 Oral Administration

Bioavailability: Usually <5% for unmodified peptides; up to 1% with enhancers

Onset of action: 30-60 minutes

Duration: Hours

Major challenges:

  • Gastric acid degradation: pH 1-3 denatures most peptides
  • Proteolytic enzymes: Pepsin, trypsin, chymotrypsin break peptide bonds
  • Poor membrane permeability: Peptides are hydrophilic and don't cross lipid membranes easily
  • First-pass metabolism: Liver degrades absorbed peptides before systemic circulation

Successful oral peptides:

  • Semaglutide (Rybelsus): Uses SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) absorption enhancer
  • Desmopressin tablets: 0.1-0.2% bioavailability (but sufficient for therapeutic effect)
  • Cyclosporine: Cyclic structure provides oral stability

Enhancement strategies:

  • Absorption enhancers (SNAC, surfactants)
  • Protease inhibitors
  • Enteric coating (pH-sensitive release)
  • Cyclization (improves stability)
  • D-amino acid substitution (resists proteases)
  • PEGylation (polyethylene glycol conjugation)

Advantages:

  • Most convenient and patient-friendly
  • No needles - improves compliance
  • Easy to self-administer
  • No injection site reactions

Disadvantages:

  • Very low bioavailability for most peptides
  • Variable absorption (food, pH, motility)
  • Requires absorption enhancers
  • Large doses needed (expensive)

👃 Intranasal Administration

Bioavailability: 10-60% (highly peptide-dependent)

Onset of action: 5-15 minutes

Duration: Minutes to hours

Mechanisms of absorption:

  • Transcellular: Across nasal epithelial cells
  • Paracellular: Between epithelial cells via tight junctions
  • Olfactory pathway: Direct nose-to-brain transport bypassing BBB

FDA-approved intranasal peptides:

  • Desmopressin (DDAVP): Diabetes insipidus, bedwetting
  • Calcitonin (Fortical/Miacalcin): Osteoporosis (note: FDA withdrew approval due to cancer concerns)
  • Oxytocin: Labor induction (less common now)

Research/off-label intranasal peptides:

  • Semax (nootropic - approved in Russia)
  • Selank (anxiolytic - approved in Russia)
  • Insulin (studied for Alzheimer's disease)
  • Oxytocin (social anxiety, autism research)

Advantages:

  • Non-invasive and painless
  • Rapid absorption and onset
  • Bypasses first-pass hepatic metabolism
  • Direct nose-to-brain pathway for CNS-active peptides
  • Easy self-administration
  • Good for pediatric and needle-phobic patients

Disadvantages:

  • Variable absorption (nasal congestion, anatomy)
  • Nasal irritation with repeated use
  • Limited dose volume (~200 mcL per nostril)
  • Mucociliary clearance reduces contact time
  • Not suitable for all peptides

Enhancement strategies:

  • Absorption enhancers (chitosan, cyclodextrins)
  • Mucoadhesive formulations
  • Enzyme inhibitors
  • Permeation enhancers

👅 Sublingual/Buccal Administration

Location: Under tongue (sublingual) or against cheek (buccal)

Bioavailability: 10-50% (peptide-dependent)

Onset of action: 10-30 minutes

Mechanism: Direct absorption through oral mucosa into systemic circulation, bypassing first-pass metabolism.

Examples:

  • Desmopressin sublingual tablets
  • Oxytocin (research formulations)
  • Some small peptide analgesics

Advantages:

  • Avoids gastric degradation
  • Bypasses first-pass metabolism
  • Fast absorption
  • Easy to administer
  • Can be removed if needed (sublingual tablets)

Disadvantages:

  • Limited to small peptides
  • Taste issues
  • Salivary washout reduces absorption
  • Cannot eat/drink during administration
  • Variable absorption

🩹 Transdermal Administration

Bioavailability: 5-80% (with enhancement technologies)

Onset of action: Hours

Duration: Hours to days

Major barrier: Stratum corneum (outermost skin layer) prevents passage of hydrophilic molecules like peptides.

Enhancement technologies:

  • Microneedles: Tiny needles (50-900 μm) create microchannels in skin
  • Iontophoresis: Electrical current drives charged peptides through skin
  • Ultrasound (sonophoresis): Acoustic waves enhance permeability
  • Chemical enhancers: Surfactants, solvents disrupt lipid barrier
  • Electroporation: Brief electrical pulses create pores

Examples:

  • GHK-Cu topical formulations (cosmetic)
  • Matrixyl, Argireline (cosmetic peptides)
  • Calcitonin (experimental patches)
  • Insulin (microneedle patches in development)

Advantages:

  • Non-invasive and painless
  • Sustained, controlled release
  • Avoids first-pass metabolism
  • Convenient for chronic treatment
  • Can be removed if adverse effects occur

Disadvantages:

  • Skin barrier severely limits permeation
  • Slow onset
  • Skin irritation/sensitization
  • Requires enhancement technology for most peptides
  • Limited to potent peptides

🫁 Pulmonary (Inhalation) Administration

Bioavailability: 10-60%

Onset of action: Minutes

Delivery device: Nebulizer, metered-dose inhaler, dry powder inhaler

Mechanism: Absorption through alveolar epithelium (large surface area ~100 m²)

Examples:

  • Insulin inhalation (Afrezza - FDA approved)
  • Calcitonin (experimental)
  • Various peptide therapeutics in development

Advantages:

  • Non-invasive
  • Large absorptive surface area
  • Rapid absorption
  • Avoids first-pass metabolism
  • Direct delivery to lungs for respiratory diseases

Disadvantages:

  • Requires special devices
  • Technique-dependent
  • Lung irritation/cough
  • Not suitable for patients with lung disease
  • Variable deposition and absorption
  • Peptide aggregation issues

👁️ Ocular (Eye) Administration

Form: Eye drops, gels, inserts

Bioavailability: <5% systemic; local delivery preferred

Examples:

  • Cyclosporine (Restasis) - dry eye
  • Experimental peptide antibiotics

Primary use: Local ocular effects rather than systemic delivery

Choosing the Right Route

Route selection depends on multiple factors:

Decision Factors

  • Peptide properties: Molecular weight, stability, lipophilicity
  • Therapeutic goal: Rapid vs sustained effect, local vs systemic
  • Bioavailability requirements: Potency of peptide
  • Patient factors: Age, ability to self-administer, needle phobia
  • Compliance: Daily injections vs weekly vs oral
  • Cost: Injectable formulations often more expensive
  • Setting: Home use vs clinical administration
Route Bioavailability Onset Best For Patient Compliance
IV 100% Immediate Emergency, hospital use Low (requires medical staff)
IM 85-100% 10-20 min Depot formulations Medium
SC 70-90% 15-30 min Chronic treatment, home use High
Intranasal 10-60% 5-15 min CNS delivery, rapid onset Very High
Oral <5% 30-60 min Chronic treatment, convenience Very High
Sublingual 10-50% 10-30 min Rapid onset without injection High
Transdermal 5-80%* Hours Sustained release, topical Very High
Pulmonary 10-60% Minutes Lung diseases, rapid systemic Medium

*With enhancement technologies

The Blood-Brain Barrier & Peptide Delivery to the CNS

The blood-brain barrier (BBB) is one of the most significant challenges in delivering therapeutic peptides to the central nervous system (CNS). Understanding the BBB and strategies to bypass or penetrate it is critical for treating neurological conditions.

What is the Blood-Brain Barrier?

Definition

The blood-brain barrier is a highly selective semipermeable border of endothelial cells that separates circulating blood from the brain extracellular fluid in the CNS. It protects the brain from potentially harmful substances while allowing essential nutrients to pass.

Structure of the BBB

The BBB consists of:

  • Endothelial cells: Tightly joined with minimal gaps, unlike peripheral capillaries
  • Tight junctions: Protein complexes (occludin, claudins, ZO-1) that seal spaces between cells
  • Basement membrane: Extracellular matrix providing structural support
  • Pericytes: Contractile cells regulating blood flow and BBB integrity
  • Astrocyte end-feet: Glial cells that ensheath capillaries and regulate BBB function

Why Most Peptides Cannot Cross the BBB

Barrier Properties Preventing Peptide Passage

  • Molecular size limit: BBB restricts molecules >400-500 Da. Most therapeutic peptides are 500-10,000+ Da
  • Hydrophilicity: Peptides are polar/charged and cannot cross lipid membranes
  • Tight junctions: No paracellular (between-cell) passage
  • Low lipophilicity: Need log P > 0 to cross; peptides typically hydrophilic
  • Lack of active transporters: Most peptides lack specific BBB transporters
  • Efflux pumps: P-glycoprotein and other efflux transporters actively pump out molecules that do penetrate

What CAN Cross the BBB?

Small, lipophilic molecules readily cross the BBB via passive diffusion. Criteria for BBB penetration:

Property Ideal for BBB Penetration Most Peptides
Molecular Weight <400-500 Da 500-10,000+ Da
Lipophilicity (log P) 1.5 to 2.7 <0 (hydrophilic)
Polar Surface Area <90 Ų >90 Ų
Hydrogen Bonds <8-10 Many (>10)
Charge Neutral at pH 7.4 Often charged

Peptides That CAN Cross the BBB (Naturally or Modified)

Small, Lipophilic Peptides

A few naturally small or modified peptides can cross the BBB:

  • Delta-Sleep-Inducing Peptide (DSIP): Small (9 amino acids, 848 Da), naturally crosses BBB after IV/SC administration. Modulates sleep-wake cycles and stress response.
  • Melanocyte-stimulating hormones (α-MSH, β-MSH): Small peptides that cross BBB and affect appetite, inflammation, neuroprotection.
  • Angiotensin II: Octapeptide (1046 Da) with limited BBB penetration at circumventricular organs (areas with leaky BBB).
  • Vasopressin & Oxytocin: Small nonapeptides with some BBB penetration, especially at high concentrations or specific brain regions.

Strategies to Deliver Peptides to the Brain

1. Intranasal Delivery (Nose-to-Brain)

Most Practical Non-Invasive Method

Mechanism: Direct transport from nasal cavity to brain via olfactory and trigeminal nerve pathways, completely bypassing the BBB.

Pathways:

  • Olfactory pathway: Along olfactory nerve fibers through cribriform plate directly into olfactory bulb
  • Trigeminal pathway: Along trigeminal nerve branches to brainstem and higher brain regions
  • Systemic absorption: Some absorption into blood (lower brain concentrations)

Successfully delivered peptides:

  • Insulin: Intranasal insulin for Alzheimer's disease (Phase 2/3 trials showing cognitive benefits)
  • Oxytocin: Social cognition, autism spectrum disorder research
  • Semax (Pro-Gly-Pro): Nootropic approved in Russia - enhances BDNF, dopamine, improves cognition
  • Selank: Anxiolytic peptide approved in Russia - modulates GABA and enkephalins
  • Desmopressin: Approved for bedwetting (central mechanism)

Advantages:

  • Non-invasive, patient-friendly
  • Direct brain delivery without systemic exposure
  • Rapid onset (minutes)
  • Bypasses hepatic first-pass metabolism
  • Avoids BBB entirely

Limitations:

  • Limited to relatively small peptides (<5-10 kDa)
  • Variable absorption (anatomy, nasal congestion)
  • Requires proper administration technique
  • Mucociliary clearance reduces contact time

2. Receptor-Mediated Transcytosis

Mechanism: Peptides conjugated to antibodies or ligands that bind BBB receptors (transferrin, insulin, LRP1 receptors), triggering receptor-mediated endocytosis and transport across BBB.

Examples:

  • Transferrin receptor antibodies: Bind transferrin receptors on BBB endothelium
  • Insulin receptor antibodies: Hijack insulin transport system
  • Angiopep-2: LRP1 receptor ligand used to shuttle cargo across BBB

Status: Experimental - several candidates in clinical trials for brain tumors, Alzheimer's, Parkinson's

3. Cell-Penetrating Peptides (CPPs)

Mechanism: Short peptides (5-30 amino acids) rich in positively charged amino acids (arginine, lysine) that can translocate across cell membranes and the BBB.

Examples:

  • TAT peptide: From HIV-1 TAT protein (GRKKRRQRRRPPQ) - widely studied for cargo delivery
  • Penetratin: From Antennapedia homeodomain
  • Polyarginine (R8-R12): Simple arginine repeats
  • Angiopep-2: Dual function - CPP and receptor-mediated transcytosis

Application: Conjugate therapeutic peptide to CPP for enhanced BBB penetration

Status: Preclinical and early clinical development

4. Lipidation & Chemical Modification

Approach: Modify peptides to increase lipophilicity, allowing passive BBB diffusion.

Strategies:

  • Fatty acid conjugation: Attach lipid chains (palmitate, stearate)
  • PEGylation: Can paradoxically help some peptides (though usually reduces BBB penetration)
  • Cyclization: Conformational constraint improves stability and sometimes BBB penetration
  • D-amino acid substitution: Increases protease resistance
  • Methylation: Add methyl groups to reduce polarity

Trade-off: Increasing lipophilicity may reduce solubility and alter bioactivity

5. Nanoparticle Carriers

Approach: Encapsulate peptides in nanoparticles (liposomes, polymeric nanoparticles, exosomes) that can cross BBB.

Mechanisms:

  • Adsorptive-mediated transcytosis: Positively charged nanoparticles
  • Receptor-mediated transcytosis: Nanoparticles decorated with targeting ligands
  • Transient BBB opening: Nanoparticles that temporarily open tight junctions

Advantages:

  • Protects peptide from degradation
  • Controlled release
  • Can deliver large peptides/proteins
  • Targetable with surface modifications

Status: Extensive research; few clinical applications yet

6. Transient BBB Disruption

Approaches:

  • Focused ultrasound + microbubbles: Transient, localized BBB opening (FDA approved for essential tremor, brain tumors)
  • Osmotic disruption: Mannitol infusion temporarily opens BBB (invasive - requires intra-arterial catheter)
  • Bradykinin analogs (RMP-7): Temporarily increase BBB permeability

Advantages: Can deliver any peptide/drug during window of permeability

Disadvantages:

  • Invasive
  • Non-selective (allows unwanted substances too)
  • Potential neurotoxicity
  • Temporary effect

Status: Used for brain tumor treatment; experimental for other conditions

7. Direct CNS Injection

Routes:

  • Intrathecal (IT): Into cerebrospinal fluid via spinal tap
  • Intracerebroventricular (ICV): Into brain ventricles via Ommaya reservoir
  • Intraparenchymal: Directly into brain tissue (e.g., convection-enhanced delivery)

Examples:

  • Intrathecal baclofen (GABA analog) for spasticity
  • Ziconotide (synthetic cone snail peptide) for chronic pain
  • Experimental enzyme replacement therapies

Advantages: Direct brain delivery, high local concentrations

Disadvantages: Highly invasive, infection risk, requires neurosurgery/repeated procedures

Peptides with Demonstrated CNS Activity

FDA-Approved or Clinically Used CNS Peptides

Peptide BBB Mechanism Route Indication
Desmopressin Intranasal to brain Intranasal Bedwetting (central vasopressin effect)
Ziconotide Direct CNS injection Intrathecal Severe chronic pain
Oxytocin Intranasal delivery Intranasal/IV Labor induction; autism research
Melanocortins Natural BBB penetration (small size) IV/SC Research: neuroprotection, appetite
DSIP Natural BBB penetration (848 Da) IV/SC Sleep regulation (research)

Investigational/Research CNS Peptides

  • Semax (MEHFPGP): Intranasal - cognitive enhancement, neuroprotection (approved Russia)
  • Selank (TKPRPGP): Intranasal - anxiolytic, immune modulation (approved Russia)
  • Dihexa: Oral/intranasal - extremely potent nootropic (preclinical)
  • P21: Intranasal - memory enhancement via CNTF pathway (early research)
  • Cerebrolysin: IV - neurotrophic peptide mixture (approved in 44+ countries, not US)
  • Insulin (intranasal): Alzheimer's disease - Phase 2/3 trials showing promise
  • NAP (davunetide): Intranasal - neuroprotection (failed Phase 3 for schizophrenia but showed safety)

Future Directions

CNS peptide delivery remains an active area of research. Promising developments include:

  • Exosome-based delivery: Natural nanovesicles that can cross BBB
  • Focused ultrasound advancement: Non-invasive, MRI-guided BBB opening
  • Intranasal formulation optimization: Mucoadhesive, permeation enhancers
  • Bispecific antibodies: Simultaneously bind BBB receptor + therapeutic target
  • Gene therapy: Deliver genes encoding therapeutic peptides directly to brain
  • Stapled peptides: Conformationally constrained for improved BBB penetration

⚠️ Important Considerations

Most "nootropic" peptides claiming CNS effects are:

  • Not FDA approved in the US
  • Have limited human safety/efficacy data
  • Often require intranasal administration for brain delivery
  • May have unproven mechanisms of BBB penetration
  • Should only be used under medical supervision

The BBB exists to protect the brain. Bypassing it carries inherent risks and should be approached cautiously.

Storage & Handling

Proper storage is essential to maintain peptide stability and efficacy. Improper handling can lead to degradation and loss of potency.

General Storage Guidelines

❄️ Lyophilized (Freeze-Dried) Peptides

  • Temperature: -20°C to -80°C (freezer)
  • Duration: 1-2 years typically
  • Protection: Moisture, light, air
  • Note: Most stable form for long-term storage

💧 Reconstituted Peptides

  • Temperature: 2-8°C (refrigerator)
  • Duration: Varies (typically 7-30 days)
  • Container: Sterile vial, protected from light
  • Note: Use bacteriostatic water for longer stability

💉 Pre-filled Injections

  • Temperature: Follow manufacturer guidelines (usually refrigerated)
  • Duration: Check expiration date
  • Transport: Keep cool during transport
  • Note: Do not freeze pre-filled pens

⚠️ Signs of Degradation

  • Color change (yellowing, darkening)
  • Cloudiness or particulates in solution
  • Clumping or caking of lyophilized powder
  • Unusual odor
  • Past expiration date

If you observe any of these signs, do not use the peptide.

Reconstitution Best Practices

  1. Use sterile bacteriostatic water or sterile water for injection
  2. Allow lyophilized peptide to reach room temperature first
  3. Add water slowly down the side of vial (don't spray directly on powder)
  4. Gently swirl (don't shake vigorously)
  5. Allow to fully dissolve before use
  6. Label with reconstitution date

Safety Considerations

While peptides generally have favorable safety profiles compared to small molecule drugs, proper precautions are essential.

Medical Supervision

Always consult a qualified healthcare provider before starting any peptide therapy. Self-medication without medical supervision can be dangerous.

General Safety Guidelines

  • Source Verification: Only obtain peptides from reputable, licensed suppliers
  • Quality Testing: Verify Certificate of Analysis (CoA) before use
  • Dosing Accuracy: Use precise measuring tools (insulin syringes, calibrated scales)
  • Injection Safety: Use sterile technique, rotate injection sites
  • Monitoring: Regular lab work and medical check-ups during therapy
  • Drug Interactions: Inform your doctor of all medications and supplements

When to Seek Medical Attention

Contact your healthcare provider immediately if you experience:

  • Severe allergic reactions (difficulty breathing, swelling, hives)
  • Persistent injection site reactions
  • Unusual symptoms or side effects
  • Signs of infection at injection site
  • Symptoms of hypoglycemia (if using metabolic peptides)

Glossary of Terms

Amino Acid
Organic compounds that combine to form proteins and peptides. There are 20 standard amino acids.
Bioavailability
The fraction of an administered dose that reaches systemic circulation unchanged.
GLP-1 (Glucagon-Like Peptide-1)
An incretin hormone that stimulates insulin secretion and regulates appetite.
Half-Life
The time required for the concentration of a drug to decrease by half in the bloodstream.
HPLC Purity
Percentage of desired peptide in a sample as measured by high-performance liquid chromatography.
Lyophilization
Freeze-drying process used to preserve peptides by removing water under vacuum.
Peptide Bond
The chemical bond linking amino acids together in a peptide chain.
Receptor
A protein on the cell surface or inside cells that binds specific molecules (like peptides) to trigger cellular responses.
Sequence
The specific order of amino acids in a peptide, typically written using single-letter codes (e.g., HAEGTFT).
SPPS (Solid-Phase Peptide Synthesis)
Chemical method for synthesizing peptides by sequentially adding amino acids to a solid support.